INDIRECT COMPARISON OF DARATUMUMAB MONOTHERAPY VERSUS REAL-WORLD HISTORICAL CONTROL DATA IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE HEAVILY PRE-TREATED AND HIGHLY REFRACTORY

被引：1
|
作者：
Diels, J. [1 ]
Lam, A. [2 ]
Ito, T. [3 ]
Ng, Y. [2 ]
Mehra, M. [2 ]
Khan, I [4 ]
机构：
[1] Janssen Hlth Econ & Market Access EMEA Stat & Mod, Beerse, Belgium
[2] Janssen Global Serv LLC, Raritan, NJ USA
[3] Janssen Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
[4] Janssen Res & Dev LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1659
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN37
引用
收藏
页码：A140 / A140
页数：1
相关论文
共 50 条
  • [41] Real-World Data in Relapsed Refractory Myeloma Patients Treated with Pomalidomide, a Multicenter Turkish Experience
    Ozsan, Guner Hayri
    Sevindik, Omur Gokmen
    Sadri, Sevil
    Hacioglu, Sibel Kabukcu
    Kaya, Sureyya Yigit
    Geduk, Ayfer
    Ural, Ali Ugur
    Tuglular, Tulin F.
    Ozkocaman, Vildan
    Demir, Ahmet Muzaffer
    Aydin, Yildiz
    Cagliyan, Gulsum Akgun
    Aydogdu, Ismet
    Pehlivan, Mustafa
    Yaradilmis, Ibrahim Muaz
    Karakus, Volkan
    Yilmaz, Mehmet
    Beksac, Meral
    [J]. BLOOD, 2017, 130
  • [42] Real-World Data in Relapsed Refractory Myeloma Patients Treated with Carfilzomib, a Multicenter Turkish Experience
    Sevindik, Omur Gokmen
    Pehlivan, Mustafa
    Tuglular, Tulin F.
    Solmaz, Serife M.
    Dogu, Mehmet Hilmi
    Yalniz, Fevzi
    Ural, Ali Ugur
    Yegen, Zafer Serenli
    Arat, Mutlu
    Ozkocaman, Vildan
    Umit, Elif G.
    Haydaroglu, Handan
    Sonmez, Sahin Mehmet
    Turgut, Mehmet
    Ozcan, Muhit
    Arslan, Onder
    Aydin, Yildiz
    Elibol, Tayfun
    Olgun, Aybuke Harmandali
    Bayar, Banu
    Tombak, Anil
    Aydogdu, Ismet
    Ozsan, Guner Hayri
    [J]. BLOOD, 2017, 130
  • [43] Evaluation of Efficacy Outcomes Among Relapsed/ Refractory Multiple Myeloma Treated Patients in a Real-World Setting
    Nooka, Ajay
    Voorhees, Peter M.
    Kumar, Shaji K.
    Mehra, Maneesha
    Lam, Annette
    Slavcev, Mary
    Ukropec, Jon
    Potluri, Ravi
    Dasgupta, Anandaroop
    [J]. BLOOD, 2017, 130
  • [44] Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy
    Khadadah, Fatima M.
    Cerquozzi, Sonia
    Olney, Harold J.
    Fraga, Christina
    Dudebout, Jill
    Xenocostas, Anargyros
    Finn, Nicholas
    Ethier, Vincent
    Savoie, M. Lynn
    Busque, Lambert
    Jamani, Kareem
    Kuruvilla, Philip
    Faught, Carolyn
    Leber, Brian
    Kaedbey, Rayan
    Assouline, Sarit E.
    Kim, Dennis
    [J]. LEUKEMIA RESEARCH, 2023, 133
  • [45] Real-World Outcome of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma: A Multicenter Propensity Score Matched Case Series Study
    Wang, Weida
    Hu, Yaofang
    Wang, Yun
    Chen, Xiaoqin
    Xia, Zhongjun
    [J]. BLOOD, 2022, 140 : 12589 - 12590
  • [46] Real-world outcomes in multiple myeloma (MM) patients who received subsequent therapy after daratumumab from the PREAMBLE study
    Farrell, James
    Gu, Jin
    Le, Trong Kim
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S170 - S170
  • [47] Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    Jianming He
    Heather Berringer
    Bart Heeg
    Haoyao Ruan
    Tobias Kampfenkel
    Harikumaran R. Dwarakanathan
    Stephen Johnston
    João Mendes
    Annette Lam
    Sacheeta Bathija
    Emma K. Mackay
    [J]. Advances in Therapy, 2022, 39 : 4230 - 4249
  • [48] Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    He, Jianming
    Berringer, Heather
    Heeg, Bart
    Ruan, Haoyao
    Kampfenkel, Tobias
    Dwarakanathan, Harikumaran R.
    Johnston, Stephen
    Mendes, Joao
    Lam, Annette
    Bathija, Sacheeta
    Mackay, Eric
    [J]. ADVANCES IN THERAPY, 2022, 39 (09) : 4230 - 4249
  • [49] KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with Relapsed and Refractory Multiple Myeloma (RRMM) and comparison of outcomes to KarMMa
    Goldschmidt, H.
    Jagannath, S.
    Lin, Y.
    Reece, D.
    Nooka, A.
    Senin, A.
    Rodriguez Otero, P.
    Powles, R.
    Matsue, K.
    Shah, N.
    Anderson, L., Jr.
    Wilson, K.
    Le, H., V
    Agarwal, A.
    Siegel, D. S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 93 - 93
  • [50] "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
    Katodritou, Eirini
    Vadikolia, Chrysanthi
    Lalagianni, Chrysavgi
    Kotsopoulou, Maria
    Papageorgiou, Georgia
    Kyrtsonis, Marie-Christine
    Matsouka, Panagiota
    Giannakoulas, Nikolaos
    Kyriakou, Despoina
    Karras, Georgios
    Anagnostopoulos, Nikolaos
    Michali, Evridiki
    Briasoulis, Evangelos
    Hatzimichael, Eleftheria
    Spanoudakis, Emmanouil
    Zikos, Panagiotis
    Tsakiridou, Anastasia
    Tsionos, Konstantinos
    Anargyrou, Konstantinos
    Symeonidis, Argiris
    Maniatis, Alice
    Terpos, Evangelos
    [J]. ANNALS OF HEMATOLOGY, 2014, 93 (01) : 129 - 139
12345